Clinical trial
Circuit Survival and Efficacy for Middle Molecular-weight Solute Elimination Between Nafamostat Infusion and Heparinized Saline Priming
NCT01486485 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Circuit Survival and Efficacy for Middle Molecular-weight Solute Elimination Between Nafamostat Infusion and Heparinized Saline Priming
- Lead sponsor
- Seoul National University Hospital
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- March 31, 2012
- Completion date
- August 31, 2013
- Enrollment
- 160 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.